BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Working on Answer to Mass Production of Rare, Otherwise Depleted Cannabinoid Opportunities

Company: InMed Pharmaceuticals Inc. (INM)
Category: Stock Spotlights

InMed Pharmaceuticals (NASDAQ: INM) and its subsidiary BayMedica are innovators in the field of rare cannabinoids, making them available for consumer access. InMed specializes in developing a proprietary biosynthesis system to manufacture pharmaceutical-grade cannabinoids that are otherwise too rare to be acquired in abundance. Through BayMedica, its recent acquisition, InMed also has capabilities in both yeast biosynthesis and chemical synthesis, catering to the large and growing health and wellness consumer markets. “The cannabis plant is made up of over 100 unique cannabinoids, many of which are only found in trace amounts,” reads a recent article. “With so many of these cannabinoids exhibiting the potential to fulfill several unmet medical needs industry-wide, InMed is working on the answer to mass production of rare and otherwise depleted cannabinoid opportunities. Unlike tetrahydrocannabinol (‘THC’) and cannabidiol (‘CBD’), which are found in excess within the cannabis plant, the goal for InMed and BayMedica is to use various manufacturing approaches to produce the amounts of rare cannabinoids necessary to fulfill the outstanding medical need in the industry.”

To view the full article, visit https://ibn.fm/EGVxs

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed Pharmaceuticals is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM 

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050